AEZ Share Price

Open 4.04 Change Price %
High 4.04 1 Day 0.02 0.50
Low 4.00 1 Week 0.00 0.00
Close 4.02 1 Month 0.07 1.77
Volume 23845 1 Year -0.50 -11.06
52 Week High 7.32
52 Week Low 3.10
AEZ Important Levels
Resistance 2 4.06
Resistance 1 4.04
Pivot 4.02
Support 1 4.00
Support 2 3.98
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 23.23 2.02%
MFC 23.23 2.02%
MFC 23.23 2.02%
MFC 23.23 2.02%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
DA-A 0.45 9.76%
HYD 0.37 8.82%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
MM 0.06 -14.29%
MM 0.06 -14.29%
ANX 0.07 -12.50%
ANX 0.07 -12.50%
CTU-A 0.19 -9.52%
BX 0.84 -8.70%
BX 0.84 -8.70%
TLB 3.88 -7.84%
TLB 3.88 -7.84%
More..

AEterna Zentaris, Inc. (TSE: AEZ)

AEZ Technical Analysis 3
As on 28th Feb 2017 AEZ Share Price closed @ 4.02 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.56 & Sell for SHORT-TERM with Stoploss of 4.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
AEZ Target for March
1st Target up-side 4.47
2nd Target up-side 4.79
3rd Target up-side 5.11
1st Target down-side 3.57
2nd Target down-side 3.25
3rd Target down-side 2.93
AEZ Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aezsinc.com
AEZ Address
AEZ
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Canada
Phone: 418-652-8525
Fax: 418-948-9191
Interactive Technical Analysis Chart AEterna Zentaris, Inc. ( AEZ TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AEterna Zentaris, Inc.
AEZ Business Profile
Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.